-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
TELUS reported challenging Q1 2026 results with revenue declining 0.6% to $4,989M and EPS falling to $0.09 from $0.21, missing consensus estimates of $0.22. Net income plunged 52.2% due to elevated restructuring costs of $315M. TELUS Health emerged as a standout with 11.2% revenue growth to $526M, serving as a critical diversification engine amid competitive pressures in core telecommunications. Management characterized the wireless environment as "highly promotional and irrational" with aggressive pricing tactics threatening premium brand value. The company delivered $431M in LifeWorks synergies, surpassing targets, while pursuing a $7B asset monetization program expected to fund half the fiber build costs. Net debt to EBITDA improved to 3.5x from 3.9x, progressing toward the 2027 target of 3.0x. We expect continued margin pressure from the promotional environment, though TELUS Health's growth and operational efficiency initiatives provide some offset to telecom headwinds.